Generic Norditropin FlexPro Availability

See also: Generic Norditropin Nordiflex

Norditropin FlexPro is a brand name of somatropin, approved by the FDA in the following formulation(s):

NORDITROPIN FLEXPRO (somatropin recombinant - injectable;injection)

  • Manufacturer: NOVO NORDISK INC
    Approval date: March 1, 2010
    Strength(s): 15MG/1.5ML

Has a generic version of Norditropin FlexPro been approved?

No. There is currently no therapeutically equivalent version of Norditropin FlexPro available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norditropin FlexPro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Pharmaceutical formulation
    Patent 5,849,700
    Issued: December 15, 1998
    Inventor(s): S.o slashed.rensen; Hans Holmegaard & Skriver; Lars & Hoelgaard; Annie Rassing
    Assignee(s): Novo Nordisk A/S
    A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Patent expiration dates:
    • December 15, 2015
      ✓ 
      Patent use: TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
  • Pharmaceutical formulation
    Patent 5,849,704
    Issued: December 15, 1998
    Inventor(s): S.o slashed.rensen; Hans Holmegaard & Skriver; Lars & Hoelgaard; Annie Rassing
    Assignee(s): Novo Nordisk A/S
    A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
    Patent expiration dates:
    • December 15, 2015
      ✓ 
      Patent use: TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE
      ✓ 
      Drug product
  • Automatic injection device with reset feature
    Patent 6,899,699
    Issued: May 31, 2005
    Inventor(s): Enggaard; Christian
    Assignee(s): Novo Nordisk A/S
    The present invention relates to a dose setting and expelling device comprising a drive member and a dose setting mechanism which simultaneously sets a given dose and stores the energy necessary for a subsequently driving the drive member in order to expel a dose of medicine from an injection device. According to the invention the dose setting mechanism allows adjustment in both directions, such that a given set dose can be reduced or cancelled by reversing the input motion, typically by rotating a setting member backwardly, this in contrast to the known devices which either requires an additional release mechanism or which cannot be reversed at all.
    Patent expiration dates:
    • January 2, 2022
      ✓ 
      Drug product
  • Dial-down mechanism for wind-up pen
    Patent 7,686,786
    Issued: March 30, 2010
    Inventor(s): Moller; Claus Schmidt & Enggaard; Christian Peter & Radmer; Bo & Markussen; Tom Hede
    Assignee(s): Novo Nordiks A/S
    The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising dial-up cam arranged to receive and engage with a dial-up key, wherein the dial-up cam and the dial-up key are adapted to, upon rotation of a dose setting member in a first direction, cooperate to strain the torsion spring of the injection device, and a dial-down cam arranged to receive and engage with a dial-down key, wherein the dial-down cam and the dial-down key are adapted to, upon rotation of the dose setting member in a second direction, cooperate to release the torsion spring of the injection device, the second rotation direction being opposite to the first rotation direction.
    Patent expiration dates:
    • August 3, 2026
      ✓ 
      Drug product
  • Automatic injection device with reset feature
    Patent 8,672,898
    Issued: March 18, 2014
    Assignee(s): Novo Nordisk A/S
    The present invention relates to a dose setting and expelling device comprising a drive member and a dose setting mechanism which simultaneously sets a given dose and stores the energy necessary for a subsequently driving the drive member in order to expel a dose of medicine from an injection device. According to the invention the dose setting mechanism allows adjustment in both directions, such that a given set dose can be reduced or cancelled by reversing the input motion, typically by rotating a setting member backwardly, this in contrast to the known devices which either requires an additional release mechanism or which cannot be reversed at all.
    Patent expiration dates:
    • January 2, 2022
      ✓ 
      Drug product
  • Injection device with torsion spring and rotatable display
    Patent 8,684,969
    Issued: April 1, 2014
    Assignee(s): Novo Nordisk A/S
    The present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof.
    Patent expiration dates:
    • October 20, 2025
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 31, 2014 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide
(web3)